We are pleased to share another significant step in the entrepreneurial development of Addax Biosciences: Fintech Partners, investment sub-holding controlled by SRI Group, has subscribed to a capital increase of 2.5 million euros, acquiring a 30% equity share.
Fintech Partners’ investment will support Addax in its international market development and expansion phase, as well as in extending and enhancing its research and development activities.
The investment from Fintech Partners is a major milestone in Addax’s ambitious project which proposes an innovative health science product, GAF® (Glyoxal Acid Free), built on a solid scientific and patent basis, a safe and effective alternative to Formalin.
Revolutionizing the histological fixation sector is the complex and crucial challenge that Addax has embraced and intends to pursue, supported by the strategic partnership with Fintech Partners, to achieve the goal of improving the working conditions of healthcare professionals, to the benefit of the medical team and patients.
As part of the transaction, Addax Biosciences was assisted by DLA Piper for the legal aspects, with a team led by lawyer Sira Franzini, and by Lexchance, with a team led by Enrico Sorisio, for the financial and tax aspects. Fintech Partners was assisted by Studio Villa e associati for the legal aspects, with a team led by lawyers Federico Villa, Giada Orioli and Francesca Pepa, and by Studio Zannini, with a team led by the partner Vieri Zannini, for the financial and tax aspects.
We are excited to initiate this collaboration with Fintech Partners and confident in achieving new milestones of excellence together, committed to innovation.